CompletedPhase 3NCT00104676

Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

Studying Extragonadal germ cell tumor

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: UNICANCER
Principal Investigator: Karim Fizazi, MD, PhD, MD PhD
Gustave Roussy, Cancer Campus, Grand Paris
Intervention: bleomycin sulfate(biological)
Enrollment: 263 enrolled
Eligibility: 16-120 years · All sexes
Timeline: 2003 – 2023

Study locations (24)

M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Centre Paul Papin, Angers, France
Institut Bergonie, Bordeaux, France
C.H.U. de Brest, Brest, France
Centre Regional Francois Baclesse, Caen, France
CHU de Grenoble - Hopital de la Tronche, Grenoble, France
Centre Oscar Lambret, Lille, France
Centre Leon Berard, Lyon, France
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France
Hopital Notre-Dame de Bon Secours, Metz, France
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France
Centre Antoine Lacassagne, Nice, France
Hopital Europeen Georges Pompidou, Paris, France
Hopital Tenon, Paris, France
Institut Jean Godinot, Reims, France
+9 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00104676 on ClinicalTrials.gov

Other trials for Extragonadal germ cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Extragonadal germ cell tumor →

← Back to all trials